Pharmacokinetic study of a high‐purity factor IX concentrate (Factor IX Grifols®) with a 6‐month follow up in previously treated patients with severe haemophilia B

Summary.  Optimal replacement treatment in haemophilia B patients requires a good understanding of the pharmacokinetics of factor IX (FIX).

[1]  M. Makris,et al.  Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  M. Morfini,et al.  The pharmacokinetics of coagulation factors , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  F. Lafeber,et al.  Pathogenesis of haemophilic arthropathy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  J. Korth-Bradley,et al.  Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Astermark,et al.  Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  D. Lillicrap,et al.  Recombinant Factor IX Recovery and Inhibitor Safety: A Canadian Post-licensure Surveillance Study , 2002, Thrombosis and Haemostasis.

[8]  C. Leissinger,et al.  Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B , 2002, Transfusion.

[9]  M. Köhler.  Thrombogenicity of prothrombin complex concentrates. , 1999, Thrombosis research.

[10]  S. Schulman,et al.  Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  P. Garzone,et al.  Clinical evaluation of recombinant factor IX. , 1998, Seminars in hematology.

[12]  S. Darby,et al.  Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C , 1997, The Lancet.

[13]  B. Nielsen,et al.  Recombinant Factor IX , 1997, Thrombosis and Haemostasis.

[14]  J. Katz,et al.  Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Journal of pediatric hematology/oncology.

[15]  N. Key,et al.  Factor IX inhibitors and anaphylaxis in haemophilia B , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  H. Roberts,et al.  Current management of hemophilia B. , 1993, Hematology/oncology clinics of North America.

[17]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[18]  J. Fernández,et al.  Update of 156 episodes of central nervous system bleeding in hemophiliacs. , 1992, Haemostasis.

[19]  M. Relling,et al.  Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. , 1991, Seminars in hematology.

[20]  P. Saidi,et al.  Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate. , 1991, Seminars in hematology.

[21]  L. Aledort.  Factor IX and thrombosis. , 2009, Scandinavian journal of haematology. Supplementum.